(Press-News.org) CHICAGO – The 2025 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research will be presented to William N. Hait, MD, PhD, Fellow of the AACR Academy, during the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick Place Convention Center in Chicago, Illinois.
Hait served as the global head of Janssen Research and Development and was the executive vice president, chief of external innovation, and medical safety and global public health officer at Johnson & Johnson prior to his retirement in 2024. He is being recognized with this award for his extensive contributions to cancer pharmacology, drug discovery, and precision medicine, including early recognition of adverse signal transduction events capable of driving malignant cell growth and advancements in the development of targeted therapies. His research on cyclic nucleotide phosphodiesterase, EF-2 kinase, and multidrug resistance mechanisms laid the foundation for transformative cancer treatments. As a quintessential leader in both academia and industry, Hait developed New Jersey's first and only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, Rutgers Cancer Institute, and spearheaded the development of oncology drugs that have improved outcomes for millions of cancer patients. His leadership and dedication to cancer research have profoundly shaped the field, inspired countless generations of scientists, and have propelled significant innovation in the design and development of novel cancer treatments.
The AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research was established in 2007 in honor of Margaret Foti, PhD, MD (hc), chief executive officer of the AACR, for her exemplary leadership of the AACR, and for her sustained, extraordinary dedication to the conquest of cancer through research, scholarly publications, communication, collaborations, education and training, fundraising for cancer research, and science policy. This award is presented annually to an individual whose leadership and extraordinary achievements in cancer research have made a major impact in the field.
Hait was one of the first to recognize the importance of signal transduction in cancer biology. Among his many impactful scientific contributions are the selective inhibition of cyclic nucleotide phosphodiesterase, identification, cloning, and functional characterization of the EF-2 kinase, which led to his work involving the development of the first EF-2 kinase inhibitors. In subsequent research, he uncovered the impact of p53 mutations on chemotherapy efficacy and elucidated the mechanism underlying severe reactions to doxorubicin. As a leader in the pharmaceutical industry, Hait applied his background in pharmacology and cancer medicine to oversee the development of more than 20 major pharmaceuticals, including amivantamab (Rybrevant), a bispecific antibody approved as a first-line treatment for lung cancer. Hait and his team have also focused on identifying cutting-edge early innovations to eliminate disease through prevention, interception, and treatment.
“Dr. Hait is an internationally renowned physician-scientist whose distinguished and impactful research has revolutionized cancer science and medicine for the benefit of countless patients,” said Foti. “The AACR is deeply grateful for his many years of wise counsel and steady leadership during his time as AACR President and Treasurer, which have been invaluable in guiding the organization to where it is today. I am thrilled that the selection committee has chosen Dr. Hait for this award, as he is richly deserving of this accolade.”
Hait has been a member of the AACR since 1986 and was elected a Fellow of the AACR Academy in 2013. Throughout his time as an AACR member, Hait’s unwavering dedication and remarkable leadership have had a significant impact on the organization, highlighted by his service as AACR President from 2007 to 2008. During his tenure, he launched the AACR’s Translational Cancer Medicine series of Special Conferences and cochaired the steering committee for the Cancer Biomarkers Collaborative (2007-2010), a program that united the AACR, NCI, and the U.S. Food and Drug Administration. He was later elected Treasurer of the AACR Board of Directors in 2010, a role that he has held with distinction and will hold until the AACR Business Meeting at this year’s AACR Annual Meeting.
Notably, he has provided exceptional guidance to many of the AACR’s committees and association groups, including but not limited to serving as cochair of the AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients (2024, 2025), scientific committee cochair (2006) and organizing committee cochair (2007, 2008) of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, member of the AACR New Jersey State Legislative Committee (1997-2007), member of the AACR Program Committee (1996, 2000), chair of the AACR Clinical Translational Cancer Research Committee (1995-2000), member of the AACR Annual Meeting Education Committee (1995), and member of the AACR Membership Committee (1990-1992). Further, Hait has contributed extensively to the AACR’s journals, serving as special advisor to the editor-in-chief for Cancer Prevention Research (2014-present), editor-in-chief of Clinical Cancer Research (2005-2007), and member of the editorial boards for Molecular Cancer Therapeutics and Cancer Research.
His scientific contributions have earned him numerous awards and honors, most notably the Johnson & Johnson Bill Hait Award for Oncology Evidence Generation (2024), the BioNJ Dr. Sol J. Barer Award for Vision, Innovation and Leadership (2019), recognition as a Mass General Cancer Center “the one hundred” honoree (2015), the Multiple Myeloma Research Foundation Corporate Leadership Award (2014), the Edward J. Ill Excellence in Medicine Award (2006), the American Jewish Congress Maimonides Award (2003), the Community Leaders of Distinction Award (2001), the Thomas Edison Award of Excellence (2000), New Jersey Medicine’s Person of the Year (1998), and acknowledgment in New York Magazine’s Best Doctors (2003, 2004) and America’s Top Doctors: New York Metro Area (2001, 2002, 2003). Further, Hait was elected as a member of the American Clinical and Climatological Association (2005) and the American Society of Clinical Investigation in 1993.
He earned his undergraduate degree at the University of Pennsylvania and his medical and doctoral degrees at the Medical College of Pennsylvania.
Hait’s award lecture will be held on Monday, April 28, at 4:15 p.m. CT.
END
William N. Hait, MD, Ph.D., FAACR, honored with the 2025 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
2025-04-08
ELSE PRESS RELEASES FROM THIS DATE:
Dinosaurs’ apparent decline prior to asteroid may be due to poor fossil record
2025-04-08
The idea that dinosaurs were already in decline before an asteroid wiped most of them out 66 million years ago may be explained by a worsening fossil record from that time rather than a genuine dwindling of dinosaur species, suggests a new study led by UCL researchers.
The study, published in Current Biology, analysed the fossil record of North America in the 18 million years up to the asteroid impact at the end of the Cretaceous period (between 66 and 84 million years ago).
Taken at face value, these fossils - more than 8,000 of them - suggest the number of dinosaur species peaked about 75 million years ago and then declined in the nine million years leading up to the ...
Coffee too weak? Try this!
2025-04-08
WASHINGTON, April 8, 2025 – Tens of billions of kilograms of coffee are consumed around the world each year. However, due to its very specific agricultural needs, coffee can be difficult to cultivate, and ongoing climate change threatens its growth.
To efficiently meet the high demand for coffee grounds, researchers from the University of Pennsylvania worked to optimize their use in pour-over coffee. They presented their suggestions in Physics of Fluids, by AIP Publishing.
“What we recommend is making the pour height as high as possible, while still maintaining a laminar ...
Health care practitioner bias and access to inpatient rehabilitation services among survivors of violence
2025-04-08
About The Study: In this mixed-methods qualitative study of hospital patients discharged to rehabilitation centers, significant disparities in denials for admission were observed among survivors of violence, who were disproportionally Black or Hispanic. Stigmatizing language found in medical records suggested that bias within the referral process may have contributed to these disparities. These findings underscore the need for reformed clinical documentation practices and enhanced oversight of ...
Mediterranean diet, physical activity, and bone health in older adults
2025-04-08
About The Study: In the PREDIMED-Plus trial, an energy-reduced Mediterranean diet and physical activity lifestyle intervention mitigated weight loss– and age-related bone mineral density decline among older women with metabolic syndrome compared with conventional ad libitum Mediterranean diet recommendations. Weight-loss lifestyle interventions with longer follow-up are warranted in the future to confirm these results in relation to bone health.
Corresponding author: To contact the corresponding authors, email Jesús F. García-Gavilán, Ph.D. (jesusfrancisco.garcia@urv.cat), and Jordi Salas-Salvadó, ...
PCORI commits to new patient-centered CER to empower health care decisions
2025-04-08
April 8, 2025
WASHINGTON, D.C. — Every day, millions of Americans make health care decisions without enough information to fully understand the trade-offs between approaches to care and make informed choices for themselves or their families. To help address these information gaps, the Patient-Centered Outcomes Research Institute (PCORI) has announced funding for new patient-centered comparative clinical effectiveness research (CER) studies across a range of conditions. These studies will help provide patients and caregivers with the evidence needed to make more informed health and health care decisions and more effectively manage their health.
Research ...
Researchers watch a single catalytic grain do work in real time
2025-04-08
PULLMAN, Wash. – A new way to watch catalytic reactions happen at the molecular level in real time could lead to better fundamental understanding and planning of the important reactions used in countless manufacturing processes every day.
A team of researchers from Washington State University and the U.S. Department of Energy’s Pacific Northwest National Laboratory (PNNL) used a new probing technique to look at the surface of iron as it was exposed to oxygen to find out what makes one catalyst work better than another. The work is reported in the journal, Angewandte Chemie. It could eventually help engineers tune reactions better and develop new catalysts ...
AI that measures its own uncertainty could improve liver cancer detection
2025-04-08
“These advancements, by providing more reliable and efficient diagnostic tools, may significantly impact clinical practice by addressing the ever-growing clinical demand and work pressure, while maintaining interpretability and clinical relevance.”
BUFFALO, NY – April 8, 2025 – A new editorial was published in Oncotarget, Volume 16, on April 4, 2025, titled “Deep learning-based uncertainty quantification for quality assurance in hepatobiliary imaging-based techniques.”
Dr. ...
City of Hope study demonstrates proof of concept for targeted new approach to treat pancreatic cancer
2025-04-08
LOS ANGELES — Researchers at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, have identified a new molecular target for treating pancreatic cancer, reports a Gastroenterology study published today.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest human cancers worldwide because it evades most treatments. With few therapeutic options, 90% of these patients don’t ...
Flex appeal: ‘Trade-off’ between armor and efficiency in sea turtle shells
2025-04-08
When we picture sea turtles in the wild, it’s easy to envision them as armored warriors – their hard, resilient shells serving as near-impenetrable shields against oceanic threats like sharks. These sleek, streamlined shells aren’t just defensive – they’re engineered for speed, efficiency and survival. Designed to minimize drag, they allow sea turtles to glide effortlessly through the water, dive to astonishing depths, and handle the immense pressure shifts as they surface.
A sea turtle’s ...
Spray drying tech used in instant coffee applied to high-capacity battery production
2025-04-08
The Korea Electrotechnology Research Institute (KERI) and the Korea Institute of Materials Science (KIMS) have jointly developed the 'spray drying technology-based high-performance dry electrode manufacturing technology' for the realization of high-capacity secondary batteries.
Secondary battery electrodes are made by mixing 'active materials' that store electrical energy, 'conductive additives' that help the flow of electricity, and 'binders' which act as a kind of adhesive. There are two methods for mixing these materials: the 'wet ...